key: cord-0972978-899a3mg6
authors: Park, Jae Seok; Lee, Eun Young
title: Renal side effects of COVID-19 vaccines in patients with immunoglobulin A nephropathy
date: 2022-01-13
journal: Kidney Res Clin Pract
DOI: 10.23876/j.krcp.21.233
sha: d5f711f3781e103a736676e7657dcfc6a9cdc4d0
doc_id: 972978
cord_uid: 899a3mg6

nan

mal kidney function (urine RBC, 11-20/ HPF; urine PCR, 0.543 g/g; and serum creatinine, 0.57 mg/dL). The patient was receiving treatment with losartan 50 mg per day and proteinuria and kidney function were stable (urine PCR, 0.17-0.18 g/g and serum creatinine, 0.65 mg/dL) until this event. Gross hematuria self-resolved without intervention and proteinuria level improved, but proteinuria did not return to baseline and remained higher than usual. Table 1 summarizes cases that showed renal complications after COVID-19 vaccination in patients with IgAN. We observed some important findings. First, gross hematuria can be the first manifestation of newly diagnosed IgAN in previously healthy patients. Second, IgAN flares can relapse after just single injection; however, de novo IgAN only follows a second injection. Third, the latent period from injection to gross hematuria was short (even within a day) in all cases. Fourth, increased proteinuria and serum creatinine level can accompany gross hematuria. Finally, all cases of gross hematuria occurred in patients who received the mRNA COVID-19 vaccine, not other vaccine types.

The pathogenesis of gross hematuria in IgAN is not fully understood. The present consensus 'multi-hit hypothesis' theoretically explains the pathogenesis as a four-step model: elevation of circulating galactose-deficient IgA1 (Gd- vaccine dose with a peak increase in random urine protein-to-creatinine ratio (PCR). Although urine PCR improved quickly, a complete recovery to the previous state was not seen. Serum creatinine levels were stable before and after vaccination.

Park and Lee. Renal side effects of COVID-19 vaccines in IgA nephropathy IgA1) level; production of anti-glycan antibody against Gd-IgA1; formation of an immune complex consisting of Gd-IgA1 and anti-glycan antibody; and, finally, deposition of an immune complex in the glomerular mesangium [2] . However, the role of mRNA COVID-19 vaccines in the pathogenesis of IgAN remains unclear. Considering the short latent period from injection to gross hematuria and the finding that neutralizing antibody does not increase during the 7 days after the first injection in the serum of vaccinated patients [3] , it is reasonable to postulate that gross hematuria is not associated with neutralizing antibody, but with more immediate immunologic factors such as cytokines or IgA1 anti-glycan immune responses [4] .

There have been reports of other glomerulonephritis (including Henoch-Schönlein purpura) relapse or new diagnosis after viral vector-based COVID-19 vaccines (manufactured by Oxford-AstraZeneca) [1, [5] [6] [7] ; however, all gross hematuria in patients with IgAN were reported only after an mRNA COVID-19 vaccine. The reason for this remains to be elucidated. In viral vector-based COVID-19 vaccines, the gene encoding the spike protein of severe acute respiratory syndrome coronavirus-2 is delivered to host cells by an adenovirus vector [8] . For the preexisting anti-adenovirus antibody that circulates in majority of population and can be cross-reactive with various serotypes of adenovirus, vaccine immunogenicity can be attenuated by preexisting antibody [8] . However, mRNA COVID-19 vaccines use a lipid nanoparticle as delivery vehicle (not adenovirus); therefore, interference from a preexisting antibody is not relevant to immunogenicity [8] . We assume that such differences in vaccine mechanism and immunogenicity may be one potential answer to question of why gross hematuria is reported after only a specific type of vaccine in IgAN patients.

The present case described gross hematuria and exacerbation of proteinuria without acute kidney injury following mRNA COVID-19 vaccine in an IgAN patient. To the best of our knowledge, this is the first such case report in Korea. Our findings suggest the following important points: First, gross hematuria can occur as the first manifestation of de novo IgAN even within a day after mRNA COVID-19 vaccine injection. Second, patients should be warned about the possibility of relapse or de novo IgAN before their first or second dose of mRNA COVID-19 vaccine, respectively. Third, serial assessment of urine protein and PCR for increased proteinuria and serum creatinine should be performed in at-risk patients. Finally, kidney biopsy, if indicated, should be performed to diagnose de novo IgAN. Further study is required to clarify the role of mRNA COVID-19 vaccines in the pathogenesis of IgAN.

De novo and relapsing glomerular diseases after COVID-19 vaccination: what do we know so far?

IgA nephropathy: core curriculum 2021

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy

A case of AN-CA-associated vasculitis after AZD1222

-2 vaccination: casualty or causality?

Granulomatous vasculitis after the AstraZeneca anti-SARS-CoV-2 vaccine

De Martinis M. Henoch-Schönlein purpura following the first dose of COVID-19 viral vector vaccine: a case report

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

Renal side effects of COVID-19 vaccines in IgA nephropathy

All authors have no conflicts of interest to declare. 

Jae Seok Park, https://orcid.org/0000-0002-9927-2086 Eun Young Lee, https://orcid.org/0000-0002-4513-9888